WASHINGTON — A former blockbuster diabetes pill that is subject to major safety restrictions may not be as dangerous as once thought, according to the latest analysis of the much-debated GlaxoSmithKline drug.
The Food and Drug Administration is reviewing a new interpretation of Avandia’s heart attack risk, which suggests that the drug is as safe as older diabetes drugs. At a highly unusual meeting this week, the FDA will ask a panel of experts to vote on a range of options for the drug, including lifting safety restrictions on its use.
The safety review is the latest twist in a years-long debate over Avandia that has divided medical experts. The drug was approved in 1999 and grew into a blockbuster, but regulators restricted its use due to unresolved safety questions in 2010.
Guidelines: Please keep your comments smart and civil. Don't attack other readers personally, and keep your language decent. Comments that violate these standards, or our privacy statement or visitor's agreement, are subject to being removed and commenters are subject to being banned. To post comments, you must be a registered user on toledoblade.com. To find out more, please visit the FAQ.